(NASDAQ: SXTP) 60 Degrees Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.33%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 66.02%.
60 Degrees Pharmaceuticals's earnings in 2026 is -$8,616,152.On average, 4 Wall Street analysts forecast SXTP's earnings for 2026 to be -$11,856,118, with the lowest SXTP earnings forecast at -$11,890,936, and the highest SXTP earnings forecast at -$11,669,366. On average, 4 Wall Street analysts forecast SXTP's earnings for 2027 to be -$7,676,881, with the lowest SXTP earnings forecast at -$12,339,001, and the highest SXTP earnings forecast at -$2,584,986.
In 2028, SXTP is forecast to generate -$2,152,397 in earnings, with the lowest earnings forecast at -$2,067,989 and the highest earnings forecast at -$2,215,702.